BioMark Announces Progress in Assay Validation of 200-Patient Trial

BioMark Diagnostics announced that the assay validation to analyze the clinical samples from the company’s first 200-patient trial should be completed within four weeks.

The British Columbia-based BioMark conducted its trials in Canada and Bangladesh, focusing on lung, breast and gastrointestinal cancers.

The assay’s internal standard, which meets FDA and Health Canada requirements, was established by Biopharmaceutical Research. An assay validation provides an assurance of reliability during normal use. — Michael Cipriano